Medicine (RMH) - Research Publications

Permanent URI for this collection

http://hdl.handle.net/11343/193

Filters

2021 4
2 2
Reset filters

Settings
Statistics
Citations
Author: Bajel, Ashish × Author: Ritchie, David × End date: 2021 × Start date: 2021 ×

Search Results

Now showing 1 - 4 of 4
  • Item
    No Preview Available
    Cardiovascular Risk Factors and Cardiovascular Disease after Allogeneic Haematopoietic Stem Cell Transplantation
    Kirkpatrick, L ; Verma, K ; Prabahran, A ; Bajel, A ; Routledge, D ; Ritchie, DS ; Garcia, T ; Panek-Hudson, Y (Elsevier BV, 2021-03)
  • Item
    No Preview Available
    T-Cell Replete Allogeneic Stem Cell Transplant Is an Effective Treatment Option for Patients with TP53 mutated Mantle Cell Lymphoma
    Scheffer Cliff, ER ; Lew, TE ; Blombery, P ; Dickinson, M ; Tam, CS ; Seymour, JF ; Bajel, A ; Ritchie, DS ; Khot, A (Elsevier BV, 2021-03)
  • Item
    Thumbnail Image
    Australia and New Zealand Transplant and Cellular Therapies COVID-19 vaccination consensus position statement
    Hamad, N ; Ananda-Rajah, M ; Gilroy, N ; MacIntyre, R ; Gottlieb, D ; Ritchie, D ; Harrison, S ; Kennedy, G ; Watson, AM ; Greenwood, M ; Doocey, R ; Perera, T ; Spencer, A ; Wong, E ; O'Brien, T ; Shaw, P ; Conyers, R ; Milliken, S ; Bardy, P ; Larsen, S ; Ho, PJ ; Lai, H ; Bajel, A ; Butler, J ; Tiley, C ; D'Rozario, J ; Johnston, A ; Cochrane, T ; Mills, T ; Irving, I ; Pullon, H ; Purtill, D (WILEY, 2021-08)
    Australia and New Zealand have achieved excellent community control of COVID-19 infection. In light of the imminent COVID-19 vaccination roll out in both countries, representatives of all adult and paediatric allogeneic bone marrow transplant and cellular therapy (TCT) centres as well as representatives from autologous transplant only centres in Australia and New Zealand collaborated with infectious diseases specialists with expertise in TCT on this consensus position statement regarding COVID-19 vaccination in TCT patients in Australia and New Zealand. It is our recommendation that TCT patients, should have expedited access to high-efficacy COVID-19 vaccines given that these patients are at high risk of morbidity and mortality from COVID-19 infection. We also recommend prioritising vaccination of TCT healthcare workers and household members of TCT patients. Vaccination should not replace other public health measures in TCT patients given the effectiveness of COVID-19 vaccination in TCT patients is unknown. Furthermore, given the limited available data, prospective collection of safety and efficacy data of COVID-19 vaccination in this patient group is a priority.
  • Item
    Thumbnail Image
    An atypical case of Epstein-Barr virus-positive plasma cell post-transplant lymphoproliferative disorder successfully treated with adoptive cell therapy
    Elliott, J ; Avdic, S ; Selim, AG ; Clancy, L ; Atkins, E ; Blyth, E ; Ritchie, D ; Gottlieb, D ; Bajel, A (WILEY, 2021-10)